Table 2 Patient characteristics, by subtype
From: Racial disparity in pro-metastatic tumor microenvironment in treatment naïve breast cancer
ER + /HER2- | TNBC | HER2 + | |||||||
|---|---|---|---|---|---|---|---|---|---|
White | Black | P-value | White | Black | P-value | White | Black | P-value | |
(N = 99) | (N = 101) | (N = 24) | (N = 60) | (N = 22) | (N = 23) | ||||
Institution | <0.001 | 0.07 | 0.07 | ||||||
Cornell | 16 (16.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (9.1%) | 0 (0%) | |||
Montefiore | 16 (16.2%) | 48 (47.5%) | 7 (29.2%) | 34 (56.7%) | 3 (13.6%) | 8 (34.8%) | |||
MSKCC | 52 (52.5%) | 44 (43.6%) | 16 (66.7%) | 24 (40.0%) | 9 (40.9%) | 12 (52.2%) | |||
NYU | 15 (15.2%) | 9 (8.9%) | 1 (4.2%) | 2 (3.3%) | 8 (36.4%) | 3 (13.0%) | |||
Distant recurrence | 0.05 | 0.92 | 0.007 | ||||||
Yes | 53 (53.5%) | 39 (38.6%) | 13 (54.2%) | 30 (50.0%) | 16 (72.7%) | 7 (30.4%) | |||
No | 46 (46.5%) | 62 (61.4%) | 11 (45.8%) | 30 (50.0%) | 6 (27.3%) | 16 (69.6%) | |||
Age (years) | 0.64 | 0.86 | 0.56 | ||||||
Mean (SD) | 56.2 (13.5) | 57.3 (13.9) | 60.0 (15.5) | 59.0 (11.9) | 56.4 (13.9) | 54.1 (11.3) | |||
Median | 56 | 58 | 63 | 57 | 55.5 | 55 | |||
[Min, Max] | [26.0, 89.0] | [29.0, 88.0] | [36.0, 89.0] | [36.0, 84.0] | [30.0, 76.0] | [34.0, 73.0] | |||
Body mass index | 0.02 | <0.001 | 0.08 | ||||||
Mean (SD) | 27.6 (6.42) | 29.3 (5.98) | 24.4 (4.10) | 32.3 (6.69) | 29.3 (6.34) | 33.9 (8.10) | |||
Median | 26.3 | 28.3 | 23.2 | 32.1 | 30.3 | 32.7 | |||
[Min, Max] | [18.7, 51.7] | [15.4, 43.9] | [19.1, 32.8] | [21.1, 56.8] | [17.5, 41.0] | [22.0, 51.1] | |||
Missing | 17 (17.2%) | 0 (0%) | 0 (0%) | 1 (1.7%) | 2 (9.1%) | 2 (8.7%) | |||
Time to distant recurrence (months) | 0.02 | 0.84 | 0.06 | ||||||
Mean (SD) | 53.9 (35.3) | 36.9 (33.0) | 24.4 (21.5) | 25.9 (20.2) | 54.9 (36.6) | 29.0 (24.5) | |||
Median | 51 | 30 | 14 | 19.5 | 43 | 28 | |||
[Min, Max] | [3, 163] | [0, 133] | [1, 77] | [2, 89] | [2, 136] | [0, 60] | |||
Surgery type | 0.4 | 0.11 | 0.33 | ||||||
BCT/Lumpectomy | 56 (56.6%) | 64 (63.4%) | 14 (58.3%) | 43 (71.7%) | 8 (36.4%) | 13 (56.5%) | |||
Lumpectomy followed by mastectomy | 1 (1.0%) | 0 (0%) | 1 (4.2%) | 6 (10.0%) | 1 (4.5%) | 2 (8.7%) | |||
Mastectomy | 41 (41.4%) | 37 (36.6%) | 9 (37.5%) | 10 (16.7%) | 13 (59.1%) | 8 (34.8%) | |||
Missing | 1 (1.0%) | 0 (0%) | 0 (0%) | 1 (1.7%) | 0 (0%) | 0 (0%) | |||
Radiation | 1 | 0.23 | 0.22 | ||||||
Yes | 67 (67.7%) | 69 (68.3%) | 16 (66.7%) | 49 (81.7%) | 10 (45.5%) | 16 (69.6%) | |||
No | 27 (27.3%) | 28 (27.7%) | 8 (33.3%) | 11 (18.3%) | 11 (50.0%) | 7 (30.4%) | |||
Missing | 5 (5.1%) | 4 (4.0%) | 0 (0%) | 0 (0%) | 1 (4.5%) | 0 (0%) | |||
Tumor stage (pT) | 0.41 | 0.66 | 0.45 | ||||||
T1 ( < 2 cm) | 48 (48.5%) | 50 (49.5%) | 14 (58.3%) | 34 (56.7%) | 8 (36.4%) | 13 (56.5%) | |||
T2 (2–5 cm) | 48 (48.5%) | 44 (43.6%) | 10 (41.7%) | 24 (40.0%) | 12 (54.5%) | 9 (39.1%) | |||
T3 ( > 5 cm) | 3 (3.0%) | 7 (6.9%) | 0 (0%) | 2 (3.3%) | 2 (9.1%) | 1 (4.3%) | |||
Lymph node status (pN) | 0.2 | 0.76 | 0.23 | ||||||
Positive | 47 (47.5%) | 58 (57.4%) | 10 (41.7%) | 29 (48.3%) | 11 (50.0%) | 8 (34.8%) | |||
Negative | 49 (49.5%) | 40 (39.6%) | 14 (58.3%) | 31 (51.7%) | 9 (40.9%) | 15 (65.2%) | |||
Missing | 3 (3.0%) | 3 (3.0%) | 0 (0%) | 0 (0%) | 2 (9.1%) | 0 (0%) | |||
Tumor grade | 0.32 | 1 | 0.67 | ||||||
High | 43 (43.4%) | 53 (52.5%) | 20 (83.3%) | 54 (90.0%) | 18 (81.8%) | 20 (87.0%) | |||
Low-intermediate | 54 (54.5%) | 48 (47.5%) | 3 (12.5%) | 6 (10.0%) | 4 (18.2%) | 3 (13.0%) | |||
Missing | 2 (2.0%) | 0 (0%) | 1 (4.2%) | 0 (0%) | 0 (0%) | 0 (0%) | |||
Follow up time (months) | 0.69 | 0.98 | 0.23 | ||||||
Mean (SD) | 102 (46.4) | 100 (50.6) | 97.6 (56.7) | 96.3 (59.2) | 95.2 (42.7) | 114 (47.7) | |||
Median | 97.7 | 103 | 112 | 106 | 85.2 | 122 | |||
[Min, Max] | [12, 198] | [3, 204] | [17, 165] | [10, 199] | [33, 182] | [30, 173] | |||
